BRPI0812494A2 - Derivados de 3',4',5-trimetóxi como estimulante da secreção de muco, método de preparação do mesmo, e composição farmacêutica compreendendo o mesmo - Google Patents

Derivados de 3',4',5-trimetóxi como estimulante da secreção de muco, método de preparação do mesmo, e composição farmacêutica compreendendo o mesmo

Info

Publication number
BRPI0812494A2
BRPI0812494A2 BRPI0812494-9A BRPI0812494A BRPI0812494A2 BR PI0812494 A2 BRPI0812494 A2 BR PI0812494A2 BR PI0812494 A BRPI0812494 A BR PI0812494A BR PI0812494 A2 BRPI0812494 A2 BR PI0812494A2
Authority
BR
Brazil
Prior art keywords
preparation
pharmaceutical composition
same
mucus secretion
secretion enhancer
Prior art date
Application number
BRPI0812494-9A
Other languages
English (en)
Inventor
Seul-Min Choi
Kyung-Koo Kang
Dong-Sung Kim
Jeong-Hoon Kim
Byoung-Ok Ahn
Moo-Hi Yoo
Mi-Jeong Seo
Ju-Mi Kim
Yong-Duck Kim
Sun-Woo Jang
Yong-Sung Shon
Original Assignee
Dong A Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong A Pharm Co Ltd filed Critical Dong A Pharm Co Ltd
Publication of BRPI0812494A2 publication Critical patent/BRPI0812494A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
BRPI0812494-9A 2007-06-07 2008-06-02 Derivados de 3',4',5-trimetóxi como estimulante da secreção de muco, método de preparação do mesmo, e composição farmacêutica compreendendo o mesmo BRPI0812494A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020070055427A KR100930467B1 (ko) 2007-06-07 2007-06-07 점액분비를 촉진시키는 3',4',5-트리메톡시 플라본 유도체화합물, 그의 제조방법 및 약학적 용도
PCT/KR2008/003078 WO2008150085A2 (en) 2007-06-07 2008-06-02 3',4',5-trimethoxy flavone derivatives as stimulant of mucus secretion, method of the same, and pharmaceutical composition comprising the same

Publications (1)

Publication Number Publication Date
BRPI0812494A2 true BRPI0812494A2 (pt) 2015-06-16

Family

ID=40094296

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0812494-9A BRPI0812494A2 (pt) 2007-06-07 2008-06-02 Derivados de 3',4',5-trimetóxi como estimulante da secreção de muco, método de preparação do mesmo, e composição farmacêutica compreendendo o mesmo

Country Status (14)

Country Link
US (1) US8203011B2 (pt)
EP (1) EP2170857B1 (pt)
JP (1) JP5295230B2 (pt)
KR (1) KR100930467B1 (pt)
CN (1) CN101679341B (pt)
AT (1) ATE529417T1 (pt)
AU (1) AU2008260829B2 (pt)
BR (1) BRPI0812494A2 (pt)
CA (1) CA2689136C (pt)
DK (1) DK2170857T3 (pt)
ES (1) ES2375184T3 (pt)
MX (1) MX2009013062A (pt)
PT (1) PT2170857E (pt)
WO (1) WO2008150085A2 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008282273A1 (en) * 2007-07-31 2009-02-05 Limerick Biopharma, Inc. Pyrone analog compositions and methods
WO2010129138A2 (en) * 2009-04-27 2010-11-11 Limerick Biopharma Phosphorylated and phosphonated pyrone analogs for therapeutic treatment
CN102796066B (zh) * 2012-08-31 2014-09-03 云南民族大学 一种黄酮类化合物及其制备方法与应用
CN103059005B (zh) * 2012-11-22 2015-04-22 中南民族大学 白杨素酰胺衍生物及其医药用途
WO2017033060A1 (en) * 2015-08-24 2017-03-02 University Of Macau Composition for treating dry eye diseases and sjögren's syndrome
CN107373745B (zh) * 2017-07-28 2020-04-03 云南中烟工业有限责任公司 一种防止烟草料液腐败变质的添加剂及其应用
KR102040810B1 (ko) * 2018-01-31 2019-11-05 인제대학교 산학협력단 알파-휴물렌을 유효성분으로 함유하는 안구 건조증 예방 또는 치료용 조성물
KR20230016533A (ko) * 2021-07-26 2023-02-02 동아제약 주식회사 레코플라본 또는 이의 염을 포함하는 피부개선용 화장료 조성물
CN117794515A (zh) 2021-08-05 2024-03-29 格里医药科技公司 用于治疗干眼综合征的包含瑞可黄酮的滴眼剂组合物及其制备方法
WO2023014117A1 (ko) 2021-08-05 2023-02-09 지엘팜텍주식회사 안구건조증 치료를 위한 레코플라본 함유 점안 조성물 및 이의 제조방법
KR102356603B1 (ko) 2021-08-05 2022-02-08 지엘팜텍주식회사 안구건조증 치료를 위한 레코플라본 함유 점안 조성물

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA873745B (en) * 1986-06-04 1988-10-26 Daiichi Seiyaku Co Benzopyran derivatives
DE3628590A1 (de) * 1986-08-22 1988-02-25 Musikon Gmbh Raumeinheit fuer die aufnahme und/oder wiedergabe von akustischen signalen
US5006550A (en) * 1989-12-29 1991-04-09 Allergan, Inc. Chroman esters of phenols and benzoic acids having retinoid-like activity
KR100447918B1 (ko) 1996-07-25 2005-09-28 동아제약주식회사 대장을포함한위장관보호작용을갖는플라본및플라바논화합물
FR2753969B1 (fr) * 1996-09-27 1998-10-30 Adir Nouveaux derives de flavones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP3957795B2 (ja) 1996-10-04 2007-08-15 興和株式会社 フラボン誘導体及びこれを含有する医薬
JPH11279062A (ja) * 1998-01-30 1999-10-12 Fujisawa Pharmaceut Co Ltd 眼科用剤
KR100327621B1 (ko) 1999-09-22 2002-03-15 유충식 7-카르복시메틸옥시-3',4',5-트리메톡시플라본의 제조방법
JP2001233775A (ja) * 2000-02-28 2001-08-28 Cci Corp 涙液分泌促進剤
KR20050024121A (ko) * 2003-09-04 2005-03-10 동아제약주식회사 7-카르복시메틸옥시-3',4',5-트리메톡시 플라본.일수화물, 이의 제조방법 및 용도
US8017649B2 (en) * 2005-03-11 2011-09-13 Howard Florey Institute Of Experimental Physiology And Medicine Flavonoid compounds and uses thereof
PL2444079T3 (pl) * 2005-05-17 2017-07-31 Sarcode Bioscience Inc. Kompozycje i sposoby leczenia chorób oczu

Also Published As

Publication number Publication date
WO2008150085A3 (en) 2009-02-26
US8203011B2 (en) 2012-06-19
AU2008260829B2 (en) 2012-11-08
JP5295230B2 (ja) 2013-09-18
ES2375184T3 (es) 2012-02-27
KR100930467B1 (ko) 2009-12-08
JP2010529112A (ja) 2010-08-26
DK2170857T3 (da) 2011-12-05
EP2170857B1 (en) 2011-10-19
PT2170857E (pt) 2011-12-12
ATE529417T1 (de) 2011-11-15
AU2008260829A1 (en) 2008-12-11
MX2009013062A (es) 2010-01-18
CN101679341A (zh) 2010-03-24
CA2689136C (en) 2012-11-13
EP2170857A2 (en) 2010-04-07
CN101679341B (zh) 2012-06-06
KR20080107542A (ko) 2008-12-11
US20100130448A1 (en) 2010-05-27
WO2008150085A2 (en) 2008-12-11
CA2689136A1 (en) 2008-12-11
EP2170857A4 (en) 2010-06-23

Similar Documents

Publication Publication Date Title
BRPI0812494A2 (pt) Derivados de 3',4',5-trimetóxi como estimulante da secreção de muco, método de preparação do mesmo, e composição farmacêutica compreendendo o mesmo
ZA200709251B (en) Suspension formulations comprising an active principle, a poloxamer or meroxapol surfactant and a glycol, its use for the manufacture of a medicament for treating ophthalmic disorders
NO20075660L (no) Blanding for behandling av inflammatoriske sykdommer
WO2008011836A3 (es) Soluciones oftálmicas
UA92000C2 (en) 1-benzylindole-2-carboxamide derivatives
EA200800798A1 (ru) Фармацевтические композиции, предназначенные для лечения нарушений внутреннего уха
ZA200709296B (en) Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycolotonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders
WO2009109618A3 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1
ECSP066608A (es) Suspensiones acuosas de ciclesonide para nebulización
HK1098960A1 (en) Method and composition for treating rhinitis
WO2009109616A3 (en) 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cxrl and p40
WO2009061431A3 (en) Compositions for the treatment and prevention of eyelid swelling comprising an osmotically active ingredient and a vasoconstrictor
WO2007077203A3 (en) Triterpenequinone and triterpenephenol derivatives and their application for the treatment of tumors and parasitic diseases
WO2009109654A8 (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1
WO2009041663A1 (ja) 皮膚疾患の予防及び／または治療剤
RU2008102249A (ru) Профилактический или терапевтичесский агент для корнеального /конъюнктивального заболевания
WO2008070010A3 (en) Hydroxylamine derivatives for the treatment of stroke
NO20092763L (no) Isosorbid mononitrat derivater for behandling av tarmlidelser
MXPA05014143A (es) Derivados de cumarina para el tratamiento de trastornos oftalmicos.
PT1490049E (pt) Citalopram para o tratamento da pre3ssao sanguinia elevada.
EP4234037A3 (en) Liquid compositions for peroral use comprising phosphatidylglycerol derivatives and thixotropic excipients for treating cardiac channelopathies caused by pharmacological agents
ECSP034742A (es) Combinacion de brimonidina y timolol para uso oftalmologico topico

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.